Loading
A phase 2 trial of MIT-001 plus CCRT in head and neck squamous cell carcinoma, run by MitoImmune Therapeutics, active and no longer recruiting.
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients is a phase 2 interventional study registered as NCT04651634 by MitoImmune Therapeutics, with 60 participants enrolled, started 2021-06-21 and due to reach its primary completion in 2025-12-31. Interventions recorded: MIT-001 plus CCRT.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/